Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 70/100

Failure Rate

36.4%

12 terminated/withdrawn out of 33 trials

Success Rate

62.5%

-24.0% vs industry average

Late-Stage Pipeline

21%

7 trials in Phase 3/4

Results Transparency

70%

14 of 20 completed trials have results

Key Signals

14 with results11 terminated

Enrollment Performance

Analytics

Phase 2

17(51.5%)

Phase 1

6(18.2%)

Phase 3

4(12.1%)

Phase 4

3(9.1%)

N/A

3(9.1%)

33Total

Phase 2(17)

Phase 1(6)

Phase 3(4)

Phase 4(3)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (33)

Showing 20 of 33 trials

NCT00310232Phase 3Terminated

Epoetin Alfa in Advanced Non-Small Cell Lung Cancer (EPO-CAN-20)

Role: collaborator

NCT00624312Phase 2Withdrawn

Procrit Versus Placebo to Determine Efficacy in Pre-Operative Major Surgical Oncology Operations

Role: collaborator

NCT00442260Phase 1Completed

Doxorubicin HCL Liposome Injection (DOXIL) in Combination With Abraxane in Patients With Metastatic Breast Cancer

Role: collaborator

NCT00101010Phase 2Completed

Rituximab and Combination Chemotherapy in Treating Older Patients With Diffuse Large B-Cell Lymphoma

Role: collaborator

NCT00290433Phase 2Completed

Efficacy of the HCVIDDOXIL Regimen in Patients With Newly Diagnosed Peripheral T-Cell Lymphoma

Role: collaborator

NCT00570180Phase 2Completed

Combination Bortezomib-containing Regimens in Newly Diagnosed Patients With t (4; 14) Positive Multiple Myeloma

Role: collaborator

NCT00626574Phase 4Terminated

Treating Patients With Aneurysmal SubArachnoid Hemorrhage (SAH) With Epoetin Alfa

Role: collaborator

NCT00744354Phase 1Terminated

Vorinostat, Bortezomib, and Doxorubicin Hydrochloride Liposome in Treating Patients With Relapsed or Refractory Multiple Myeloma

Role: collaborator

NCT00307294Phase 2Completed

Thalidomide and Doxil® in Patients With Androgen Independent Prostate Cancer (AIPC)

Role: collaborator

NCT00244985Phase 1Completed

Rituximab and Liposomal Doxorubicin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Role: collaborator

NCT00184002Phase 2Completed

Doxorubicin (Doxil) Combined With Rituxan, Cyclophosphamide, Vincristine and Prednisone in Newly Diagnosed Aggressive Non-Hodgkin's Lymphomas

Role: collaborator

NCT00222105Phase 2Completed

A Study Evaluating Efficacy, Toxicity, Harvest Yield and Quality of Life

Role: collaborator

NCT00258440Not ApplicableTerminated

Epoetin Alfa in Treating Patients With Anemia Who Are Undergoing Chemotherapy for Cancer

Role: collaborator

NCT00248339Phase 3Completed

Trial of Peg-interferon Plus Epoetin-alfa for Treatment of Chronic Hepatitis C Virus Infection

Role: collaborator

NCT00303108Phase 2Completed

Doxil & Carboplatin Plus HER2+ in Metastatic Breast Cancer

Role: collaborator

NCT00700531Not ApplicableCompleted

European Trial of Free Light Chain Removal by Extended Haemodialysis in Cast Nephropathy

Role: collaborator

NCT00635050Phase 2Completed

Therapy for Locally Advanced Breast Cancer Using Doxil, Paclitaxel, and Cyclophosphamide With Avastin

Role: collaborator

NCT00176293Phase 2Terminated

Randomized Phase II Trial of Doxil With or Without Dexamethasone for Metastatic Hormone Refractory Prostate Cancer

Role: collaborator

NCT00972712Phase 1Completed

Protocol of the Combination of Bortezomib and Tipifarnib for Relapsed or Refractory Multiple Myeloma

Role: collaborator

NCT00312650Phase 2Terminated

Doxil and Gemcitabine in Recurrent Ovarian Cancer

Role: collaborator